Download Files:
GDC-2394
$150 – $510
Products Details
Product Description
– GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC50s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation[1][2].
Web ID
– HY-148258
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C20H25N5O4S
References
– [1]McBride C, et al. Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor. J Med Chem. 2022 Oct 24. |[2]Stafford, et al. Preparation of hexahydroindacenylcarbamoyldihydropyrazolooxazinesulfonamide derivatives and analogs for use as interleukin-1 activity inhibitors: World Intellectual Property Organization, WO2018136890[P]. 2018-07-26.
CAS Number
– 2238822-07-4
Molecular Weight
– 431.51
Compound Purity
– 99.54
SMILES
– O=S(C1=C2OC[C@@H](NC)CN2N=C1)(NC(NC3=C4CCCC4=CC5=C3CCC5)=O)=O
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Caspase;Interleukin Related;NOD-like Receptor (NLR)
Pathway
– Apoptosis;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
